30-Day and 1-Year Mortality after Transcatheter Aortic Valve Replacement: The Impact of Balloon Aortic Valvuloplasty as a Bridging Therapy in a Portuguese Tertiary Center

Table 3

Results from univariate and multivariate Cox models at 30-day and 1-year all-cause mortality between groups.

Variables	30-day all-cause mortality				1-year all-cause mortality
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
BAV	5.19	(2.30-11.7)	3.82	(1.67–8.73)	2.55	(1.28–5.05)	1.99	(1.00–3.98)
Male	1.42	(0.75–2.69)			1.21	(0.81–1.80)
Atrial fibrillation	2.49	(1.34–4.58)	2.05	(1.11–3.82)	2.38	(1.61–3.51)	2.03	(1.36–3.02)
EuroScore II	1.06	(1.03–1.08)	1.05	(1.02–1.08)	1.05	(1.03–1.07)	1.05	(1.03–1.07)
STS score	1.01	(1.0–1.02)			1.01	(1.002–1.02)
LVEF <40%	1.44	(0.60–3.42)			1.88	(1.13–3.13)

BAV, balloon aortic valvuloplasty; CI, confidence interval; HR, hazard ratio; LVEF, left ventricular ejection fraction; STS, Society of Thoracic Surgeons.